Guo Min, Li Xiaxi, Li Jiong, Li Baolong
Department of Oncology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Department of Gastroenterology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Heliyon. 2023 Jun 12;9(6):e17101. doi: 10.1016/j.heliyon.2023.e17101. eCollection 2023 Jun.
Colorectal cancer (CRC) is the third most diagnosed malignancy and the second leading cause of cancer death. The objective was to identify novel hub genes that were helpful for prognosis and targeted therapy in CRC. GSE23878, GSE24514, GSE41657, GSE81582 were filtered from the gene expression omnibus (GEO). Differentially expressed genes (DEGs) were identified through GEO2R, which were enriched in the GO term and KEGG pathway in DAVID. PPI network was constructed and analyzed using STRING and hub genes were screened out. The relationships between hub genes and prognoses in CRC were evaluated in GEPIA based on the cancer genome atlas (TCGA) and genotype-tissue expression (GTEx). The transcription factors and miRNA-mRNA interaction networks for hub genes were performed using miRnet and miRTarBase. The relationship between hub genes and tumor-infiltrating lymphocytes were analyzed in TIMER. The protein levels of hub genes were identified in HPA. The expression levels of hub gene in CRC and its effect on the biological effect of CRC cells were identified . As hub genes, the mRNA levels of BIRC5, CCNB1, KIF20A, NCAPG, and TPX2 were highly expressed in CRC and had excellent prognostic value. The BIRC5, CCNB1, KIF20A, NCAPG, and TPX2 were closely associated with transcription factors, miRNAs, tumor-infiltrating lymphocytes, suggesting their involvement in the regulation of CRC. BIRC5 highly expressed in CRC tissues and cells, and promoted the proliferation, migration, and invasion of CRC cells. BIRC5, CCNB1, KIF20A, NCAPG, and TPX2 are hub genes that serve as promising prognostic biomarkers in CRC. BIRC5 plays an important role in the development and progression of CRC.
结直肠癌（CRC）是第三大最常被诊断出的恶性肿瘤，也是癌症死亡的第二大主要原因。目的是鉴定有助于CRC预后和靶向治疗的新型核心基因。从基因表达综合数据库（GEO）中筛选出GSE23878、GSE24514、GSE41657、GSE81582。通过GEO2R鉴定差异表达基因（DEG），这些基因在DAVID的基因本体（GO）术语和京都基因与基因组百科全书（KEGG）通路中富集。使用STRING构建并分析蛋白质-蛋白质相互作用（PPI）网络，并筛选出核心基因。基于癌症基因组图谱（TCGA）和基因型-组织表达（GTEx），在GEPIA中评估核心基因与CRC预后之间的关系。使用miRnet和miRTarBase构建核心基因的转录因子和miRNA-mRNA相互作用网络。在TIMER中分析核心基因与肿瘤浸润淋巴细胞之间的关系。在人类蛋白质图谱（HPA）中鉴定核心基因的蛋白质水平。鉴定CRC中核心基因的表达水平及其对CRC细胞生物学效应的影响。作为核心基因，BIRC5、CCNB1、KIF20A、NCAPG和TPX2的mRNA水平在CRC中高表达，并具有良好的预后价值。BIRC5、CCNB1、KIF20A、NCAPG和TPX2与转录因子、miRNA、肿瘤浸润淋巴细胞密切相关，表明它们参与CRC的调控。BIRC5在CRC组织和细胞中高表达，并促进CRC细胞的增殖、迁移和侵袭。BIRC5、CCNB1、KIF20A、NCAPG和TPX2是核心基因，可作为CRC中有前景的预后生物标志物。BIRC5在CRC的发生和发展中起重要作用。
